A new strategy for monitoring of direct oral anticoagulants in patients with cyanotic and complex congenital heart disease.

ABSTRACT:

Background

Patients with congenital heart disease (CHD) often require an oral anticoagulation. Vitamin K antagonists (VKA) are the standard treatment, however, an increased hematocrit in patients with secondary erythrocytosis due to cyanosis complicates the correct measurement of the international normalized ratio. Direct oral anticoagulants (DOAC) could be an alternative, but data on their efficacy and safety in complex and cyanotic CHD patients are scarce. This study proposes a new strategy of DOAC monitoring in these patients using D-dimers and DOAC trough levels.

Methods

This is a retrospective study including cyanotic and complex CHD patients requiring oral anticoagulation. Clinical, cardiac imaging and laboratory data were collected before and after start of DOAC. The

SUBMITTER: Dirbach F 

PROVIDER: S-EPMC11657253 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature